IRVINE, Calif., Aug. 29, 2005 (PRIMEZONE) -- "While many fear the lack of investment dollars in the stock market by retiring baby boomers, savvy investors are focusing on the areas where this enormous group will soon be spending their money," stated SmallCap Sentinel analyst, D.R. Clark. "Surely, the diminished income of retired boomers will tighten personal spending and investment but it should simultaneously cause a greater consumption of imperative goods and services led most obviously by health care."
"Companies are aggressively growing their health care related business plans with product development and licensing agreements, broadening their revenue-seeking footprint as the boomers head toward their golden years," Clark added.
Along these lines, Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation medical technology, has announced the formation of the Biophan Business Development Group to capitalize on the company's extensive intellectual property portfolio through expansion of licensing agreements to biomedical industry customers worldwide.
The informational report "Innovations in Biotechnology" is available at:
The report will address issues regarding emergent biotechnology potentially affecting companies such as Merck (NYSE:MRK), Amgen (Nasdaq:AMGN), and Pfizer Inc. (NYSE:PFE). Additional information regarding Biophan is available at: http://trilogy-capital.com/biph_summary.aspx
Individuals may also register for future reports at:
http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Biophan for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.